Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Axsome Thera One World Trade Center 22nd Floor NEW YORK NY 10007 USA

www.axsome.com Employees: 683 P: 212-332-3241 F: 212-320-0245

Sector:

Medical

Description:

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

Key Statistics

Overview:

Market Capitalization, $K 9,301,197
Enterprise Value, $K 9,166,557
Shares Outstanding, K 50,413
Float, K 39,171
% Float 77.70%
Short Interest, K 2,724
Short Float 5.40%
Days to Cover 3.84
Short Volume Ratio 0.65
% of Insider Shareholders 22.30%
% of Institutional Shareholders 81.49%

Financials:

Annual Sales, $ 385,690 K
Annual Net Income, $ -287,220 K
Last Quarter Sales, $ 170,990 K
Last Quarter Net Income, $ -47,230 K
EBIT, $ -206,040 K
EBITDA, $ -195,440 K

Growth:

1-Year Return 93.76%
3-Year Return 162.56%
5-Year Return 170.96%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -95.52%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.94 on 11/03/25
Next Earnings Date 02/17/26 [--]
Earnings Per Share ttm -3.62
EPS Growth vs. Prev Qtr -2.17%
EPS Growth vs. Prev Year 29.85%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

AXSM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 438.20
Price/Earnings to Growth 9.74
Return-on-Equity % -277.31%
Return-on-Assets % -28.81%
Profit Margin % -74.47%
Debt/Equity 1.60
Price/Sales 16.18
Price/Cash Flow N/A
Price/Book 121.21
Book Value/Share 1.46
Interest Coverage -42.70
60-Month Beta 0.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar